Overactive Bladder - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 127 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Overactive Bladder - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Overactive Bladder - Pipeline Review, H2 2014', provides an overview of the Overactive Bladder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Overactive Bladder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Overactive Bladder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Overactive Bladder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Overactive Bladder Overview 11
Therapeutics Development 12
Pipeline Products for Overactive Bladder - Overview 12
Pipeline Products for Overactive Bladder - Comparative Analysis 13
Overactive Bladder - Therapeutics under Development by Companies 14
Overactive Bladder - Therapeutics under Investigation by Universities/Institutes 16
Overactive Bladder - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Overactive Bladder - Products under Development by Companies 20
Overactive Bladder - Products under Investigation by Universities/Institutes 21
Overactive Bladder - Companies Involved in Therapeutics Development 22
Allergan, Inc. 22
Sanofi 23
Merck & Co., Inc. 24
Takeda Pharmaceutical Company Limited 25
Ipsen S.A. 26
Astellas Pharma Inc. 27
Kissei Pharmaceutical Co., Ltd. 28
Recordati S.p.A. 29
Ferring International Center S.A. 30
OPKO Health, Inc. 31
Toray Industries, Inc. 32
Addex Therapeutics Ltd 33
NeuroSearch A/S 34
TARIS BioMedical, Inc. 35
Asahi Kasei Pharma Corp. 36
Hydra Biosciences, Inc. 37
Laboratorios SALVAT S.A. 38
FemmePharma Global Healthcare, Inc. 39
Motif BioSciences, Inc. 40
Ion Channel Innovations, LLC 41
TheraVida, Inc. 42
Lipella Pharmaceuticals, Inc. 43
AltheRx Pharmaceuticals, Inc. 44
Mezzion Pharma Co. Ltd. 45
MI.TO. Technology S.r.L. 46
Dong-A Socio Group 47
Overactive Bladder - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 53
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
solifenacin succinate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(mirabegron + solifenacin succinate) - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SCH-900978 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
oxybutynin hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
abobotulinumtoxin A - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
solabegron hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MK-4618 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
senrebotase - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
(tolterodine + pilocarpine) - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
tarafenacin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
oxybutynin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
onabotulinumtoxin A liposomal - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
FE-999309 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
mirabegron ER - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
REC-1819 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pVAX-hSlo - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
REC-0438 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TRK-380 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
KEA-0477 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
udenafil - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ADX-71441 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
HC-067047 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
REC-0436 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
THVD-202 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
fesoterodine - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
solifenacin - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
darifenacin - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule to Agonize GABAB Receptor for Overactive Bladder and Pain - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
tacrolimus liposomal - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
SAR-244181 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
MTF-002 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules to Antagonize TRPV1 for Overactive Bladder - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
TD-302 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
URB-937 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
DA-8010 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
NS-19504 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Overactive Bladder - Recent Pipeline Updates 111
Overactive Bladder - Dormant Projects 118
Overactive Bladder - Discontinued Products 119
Overactive Bladder - Product Development Milestones 120
Featured News & Press Releases 120
Jun 03, 2014: Merus Labs International Notified of a Canadian ANDS Filing 120
Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder 120
Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder 120
Sep 11, 2013: Allergan's BOTOX Receives Authorisation for the Treatment of Overactive Bladder in the UK 121
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 123
May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 123
May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder 124
May 07, 2013: Astellas Pharma Presents Clinical Data On Myrbetriq At American Urological Association Annual Meeting 124
May 06, 2013: AltheRx Presents Positive Data On Experimental Combination Of Beta3-Adrenoceptor Agonists And Antimuscarinics At AUA Annual Meeting 124
Apr 23, 2013: Merus Labs Provides Enablex Operational Update 125
Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 127
Disclaimer 127

List of Tables
Number of Products under Development for Overactive Bladder, H2 2014 12
Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Investigation by Universities/Institutes, H2 2014 21
Overactive Bladder - Pipeline by Allergan, Inc., H2 2014 22
Overactive Bladder - Pipeline by Sanofi, H2 2014 23
Overactive Bladder - Pipeline by Merck & Co., Inc., H2 2014 24
Overactive Bladder - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 25
Overactive Bladder - Pipeline by Ipsen S.A., H2 2014 26
Overactive Bladder - Pipeline by Astellas Pharma Inc., H2 2014 27
Overactive Bladder - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 28
Overactive Bladder - Pipeline by Recordati S.p.A., H2 2014 29
Overactive Bladder - Pipeline by Ferring International Center S.A., H2 2014 30
Overactive Bladder - Pipeline by OPKO Health, Inc., H2 2014 31
Overactive Bladder - Pipeline by Toray Industries, Inc., H2 2014 32
Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H2 2014 33
Overactive Bladder - Pipeline by NeuroSearch A/S, H2 2014 34
Overactive Bladder - Pipeline by TARIS BioMedical, Inc., H2 2014 35
Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H2 2014 36
Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H2 2014 37
Overactive Bladder - Pipeline by Laboratorios SALVAT S.A., H2 2014 38
Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H2 2014 39
Overactive Bladder - Pipeline by Motif BioSciences, Inc., H2 2014 40
Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H2 2014 41
Overactive Bladder - Pipeline by TheraVida, Inc., H2 2014 42
Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H2 2014 43
Overactive Bladder - Pipeline by AltheRx Pharmaceuticals, Inc., H2 2014 44
Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H2 2014 45
Overactive Bladder - Pipeline by MI.TO. Technology S.r.L., H2 2014 46
Overactive Bladder - Pipeline by Dong-A Socio Group, H2 2014 47
Assessment by Monotherapy Products, H2 2014 48
Assessment by Combination Products, H2 2014 49
Number of Products by Stage and Target, H2 2014 52
Number of Products by Stage and Mechanism of Action, H2 2014 55
Number of Products by Stage and Route of Administration, H2 2014 57
Number of Products by Stage and Molecule Type, H2 2014 59
Overactive Bladder Therapeutics - Recent Pipeline Updates, H2 2014 111
Overactive Bladder - Dormant Projects, H2 2014 118
Overactive Bladder - Discontinued Products, H2 2014 119